IO Biotech
Holger Martin Strauss is a highly experienced Senior Scientist in Drug Product Development, currently working at IO Biotech. With a strong background in CMC and formulation, Holger Martin previously held positions at Evaxion Biotech A/S and Novo Nordisk. Holger's expertise includes manufacturing, analytical strategy, stability studies, and collaboration with CROs & CDMOs in the biopharmaceutical industry. Holger Martin holds a PhD in Structural Biology and Protein Biophysics from FMP Berlin.
IO Biotech
2 followers
IO Biotech is a clinical stage biotech company developing disruptive immune therapies for immunological treatment of cancer. Their pipeline of first-in-class immune modulating anti-cancer therapies is based on a unique platform technology enabling the activation of T cells that are specific for immune inhibitory molecules.